Objective: To assess the efficacy and safety of fezolinetant and elinzanetant for vasomotor symptoms in menopausal women.
Data Sources: MEDLINE, EMBASE, and Cochrane databases were systematically searched until August 22, 2024. Because the Cochrane Library included all the identified randomized controlled trials (RCTs), it was unnecessary to search ClinicalTrials.gov. The following words made up the search strategy, which was applied to the three databases: fezolinetant, elinzanetant, vasomotor symptoms, and menopause.
Methods Of Study Selection: Only RCTs comparing fezolinetant and elinzanetant with placebo for vasomotor symptoms in menopausal women were included.
Tabulation, Integration, And Results: We extracted the number of patients, mean age, body mass index (BMI), and number of patients who underwent oophorectomy. Data were examined with the Mantel-Haenszel method and 95% CIs. Heterogeneity was assessed with I2 statistics. R 4.3.2 was used for statistical analysis. Seven RCTs with 4,087 patients were included in the analysis. Fezolinetant and elinzanetant were associated with diminished vasomotor symptom frequency: fezolinetant 30 mg (mean difference 2.16, 95% CI, 1.54-2.79, I2=0%), fezolinetant 45 mg (mean difference 2.54, 95% CI, 1.86-3.21, I2=0%), and elinzanetant 120 mg (mean difference 2.99, 95% CI, 1.74-4.23, I2=0%). Both drugs also showed a decrease in vasomotor symptom severity: fezolinetant 30 mg (mean difference 0.20, 95% CI, 0.09-0.33, I2=0%), fezolinetant 45 mg (mean difference 0.24, 95% CI, 0.13-0.34, I2=0%), and elinzanetant 120 mg (mean difference 0.36, 95% CI, 0.26-0.46, I2=0%). Elinzanetant 120 mg showed a significant improvement in sleep quality (mean difference 4.65, 95% CI, 3.73-5.56, I2=0%). Elinzanetant 120 mg was associated with the occurrence of drug-related adverse events (11.70% vs 20.75%, risk ratio [RR] 0.57, 95% CI, 0.39-0.82, I2=19%) and headache (2.54% vs 8.0%, RR 0.32, 95% CI, 0.16-0.64, I2=0%).
Conclusion: In this meta-analysis, consistent results suggest that fezolinetant and elinzanetant are associated with beneficial outcomes in menopausal women with vasomotor symptoms. Elinzanetant provided a larger effect size in vasomotor symptom frequency and severity reduction and greatly improved sleep quality compared with fezolinetant.
Systematic Review Registration: PROSPERO, CRD42023469952.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/AOG.0000000000005812 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fezolinetant and Elinzanetant Therapy for Menopausal Women Experiencing Vasomotor Symptoms: A Systematic Review and Meta-analysis.
Obstet Gynecol
January 2025
Federal University of Mato Grosso, Sinop, Mato Grosso, Sciences Medical School of Santos, Santos, Santa Marcelina College of Medicine, São Paulo, and Dante Pazzanese Institute of Cardiology, São Paulo, São Paulo, Feevale University, Novo Hamburgo, Rio Grande do Sul, Santo Agostinho Faculty, Vitória da Conquista, Bahia, and Federal University of Pará, Belém, Pará, Brazil.
Objective: To assess the efficacy and safety of fezolinetant and elinzanetant for vasomotor symptoms in menopausal women.
Data Sources: MEDLINE, EMBASE, and Cochrane databases were systematically searched until August 22, 2024. Because the Cochrane Library included all the identified randomized controlled trials (RCTs), it was unnecessary to search ClinicalTrials.
[What is new on peri- and postmenopause?].
Dtsch Med Wochenschr
November 2024
Frauenklinik, Universitätsklinikum rechts der Isar, München, Germany.
Menopause is an increasingly discussed topic in recent years. More women are demanding consultancy and help from their doctors via different channels, be it online or in menopause centers.The term genitourinary syndrome of menopause (GSM) comprises vaginal and urological symptoms such as mucosal dryness, itching and burning, dysuria or bleeding and pain during sexual intercourse.
View Article and Find Full Text PDFFezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause requiring a careful evaluation of the benefit-risk balance.
Expert Opin Pharmacother
October 2024
Department of Pharmacy, Research Unit in Clinical Pharmacology and Toxicology, Namur Research Institute for Life Sciences (NARILIS), Faculty of Medicine, University of Namur, Namur, Belgium.
Article Synopsis
- Vasomotor symptoms (VMS) significantly affect the quality of life and sleep for many postmenopausal individuals.
- This systematic review assesses the safety and effectiveness of neurokinin-3 receptor antagonists like fezolinetant and elinzanetant for alleviating VMS in these patients.
- The analysis of six randomized controlled trials found that fezolinetant effectively reduced VMS frequency and severity and improved quality of life and sleep, with no serious adverse effects reported; similar positive outcomes were seen with elinzanetant.
Fezolinetant: A New Nonhormonal Treatment for Vasomotor Symptoms.
J Pharm Technol
December 2023
Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, FL, USA.
Article Synopsis
- The text reviews fezolinetant as a treatment for menopause-related vasomotor symptoms, highlighting its mechanism of action by inhibiting neurokinin B from binding to receptors in the hypothalamus.
- Clinical trials indicate that fezolinetant is more effective than a placebo at reducing both the frequency and severity of these symptoms, though it does have common side effects like headaches and gastrointestinal issues.
- With fezolinetant approved and elinzanetant in phase 3 trials, patients now have nonhormonal alternatives to hormone therapy, which may not be suitable for everyone due to associated risks.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!